Calidi Biotherapeutics Stock Performance
| CLDI Stock | 1.24 0.05 3.88% |
The firm shows a Beta (market volatility) of 1.28, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Calidi Biotherapeutics will likely underperform. At this point, Calidi Biotherapeutics has a negative expected return of -0.24%. Please make sure to confirm Calidi Biotherapeutics' treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Calidi Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Calidi Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:12 | Last Split Date 2025-08-05 |
1 | Acquisition by Leftwich Scott of 11684 shares of Calidi Biotherapeutics subject to Rule 16b-3 | 10/10/2025 |
2 | Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting | 11/04/2025 |
3 | Why Calidi Biotherapeutics Inc. stock stays undervalued - Inflation Watch Free Risk Controlled Daily Trade Plans - newser.com | 11/12/2025 |
4 | Can Calidi Biotherapeutics Inc. stock sustain institutional interest - CEO Change Safe Investment Capital Preservation Plans - Fundao Cultural do Par | 11/14/2025 |
5 | Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and QA Session on November 19, 2025 | 11/17/2025 |
6 | Will Calidi Biotherapeutics Inc. stock outperform small cap peers - Portfolio Risk Report Real-Time Volume Spike Alerts - Newser | 12/04/2025 |
7 | Disposition of 850 shares by Allan Camaisa of Calidi Biotherapeutics at 1.455 subject to Rule 16b-3 | 12/12/2025 |
| Begin Period Cash Flow | 2.2 M | |
| Total Cashflows From Investing Activities | -16 K |
Calidi Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 152.00 in Calidi Biotherapeutics on September 30, 2025 and sell it today you would lose (28.00) from holding Calidi Biotherapeutics or give up 18.42% of portfolio value over 90 days. Calidi Biotherapeutics is currently does not generate positive expected returns and assumes 4.0707% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Calidi, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Calidi Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Calidi Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Calidi Biotherapeutics, and traders can use it to determine the average amount a Calidi Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.059
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLDI |
Based on monthly moving average Calidi Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Calidi Biotherapeutics by adding Calidi Biotherapeutics to a well-diversified portfolio.
Calidi Biotherapeutics Fundamentals Growth
Calidi Stock prices reflect investors' perceptions of the future prospects and financial health of Calidi Biotherapeutics, and Calidi Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Calidi Stock performance.
| Return On Asset | -1.2 | ||||
| Current Valuation | 1.82 M | ||||
| Shares Outstanding | 7.17 M | ||||
| Price To Book | 1.28 X | ||||
| Price To Sales | 50.83 X | ||||
| Gross Profit | 31 K | ||||
| EBITDA | (19.73 M) | ||||
| Net Income | (22.21 M) | ||||
| Total Debt | 7.04 M | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (19.69 M) | ||||
| Earnings Per Share | 0.36 X | ||||
| Market Capitalization | 8.89 M | ||||
| Total Asset | 14.18 M | ||||
| Retained Earnings | (121.72 M) | ||||
| Working Capital | 731 K | ||||
About Calidi Biotherapeutics Performance
By evaluating Calidi Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Calidi Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Calidi Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Calidi Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.64) | |
| Return On Capital Employed | (4.65) | (4.41) | |
| Return On Assets | (1.56) | (1.64) | |
| Return On Equity | (14.43) | (13.71) |
Things to note about Calidi Biotherapeutics performance evaluation
Checking the ongoing alerts about Calidi Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Calidi Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Calidi Biotherapeutics generated a negative expected return over the last 90 days | |
| Calidi Biotherapeutics may become a speculative penny stock | |
| Calidi Biotherapeutics has high historical volatility and very poor performance | |
| Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| About 15.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 850 shares by Allan Camaisa of Calidi Biotherapeutics at 1.455 subject to Rule 16b-3 |
- Analyzing Calidi Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Calidi Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Calidi Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Calidi Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Calidi Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Calidi Biotherapeutics' stock. These opinions can provide insight into Calidi Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Calidi Stock analysis
When running Calidi Biotherapeutics' price analysis, check to measure Calidi Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calidi Biotherapeutics is operating at the current time. Most of Calidi Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Calidi Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calidi Biotherapeutics' price. Additionally, you may evaluate how the addition of Calidi Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |